TriangleStereotactic Radiosurgery (NCT02747303)
Stereotactic Radiosurgery trial for Brain Metastases (NCT02747303). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with one to five intact brain metastases, each no larger than three centimeters. Germ-cell tumors, small-cell cancer and blood cancers are excluded, as are specified high-risk brain locations.
The idea: compare stereotactic radiation with no extra margin against a two-millimeter margin around each tumor. Random assignment selects margins; dose depends on tumor size. Researchers measure progression-free survival at six months. Prior radiation and drug timing have restrictions.
This phase 2 study plans 166 patients. Steven Chmura leads it at the University of Chicago, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.